ABVC earnings analysis
What we found in ABVC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, or segment results, so current-period financial trends cannot be assessed from the available text. The principal disclosure is that controls remained ineffective as of June 30, 2026, with prior material misstatements and a restatement linked to an existing material weakness. Management terminated the relevant external advisor and is hiring technical accounting personnel, but remediation remains in progress and no quantitative guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No prior-period impact from control deficiency
- ABVC reported no material impact on prior-period financial statements from the internal-control deficiency identified during the quarter ended June 30, 2026.
- External advisor engagement terminated
- The company terminated the external advisor associated with the control deficiency during the quarter ended June 30, 2026.
- Control remediation plan underway
- ABVC is developing a remediation plan and is working to hire personnel with requisite technical accounting knowledge as of August 12, 2026.
- No material legal proceedings
- The company reported no material legal proceedings as of August 12, 2026.
- January equity financing completed
- ABVC issued 131,280 common shares for aggregate proceeds of $256,000 on January 12, 2026, at $1.95 per share.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weakness and restatement
- Disclosure controls were ineffective as of June 30, 2026 because of a material weakness previously described in the 2025 Form 10-K; the weakness resulted in material misstatements and a restatement.
- Ongoing reporting and market risk
- The company stated that failure to remediate the material weakness, or identification of additional weaknesses, could adversely affect its reporting and financial obligations, financial condition, and common-stock trading price.
- External-advisor oversight deficiency
- During the quarter ended June 30, 2026, ABVC identified inadequate controls over due diligence and monitoring of external advisors, including failure to timely identify regulatory or disciplinary matters.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS outlook and does not provide operating guidance.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 18, 2026
- ABVC BioPharma's Q1 2026 report reveals no revenue generation, continuing a trend from previous periods, with operating expenses increasing by 127% year-over-year. The net loss grew to $1.69 million, reflecting…
- 10-K · March 3, 2026
- ABVC is an early-stage biotech with a pipeline of seven drug candidates and one medical device, generating revenue primarily from out‑licensing IP and CDMO services. The company reported continued clinical progress…
- 10-Q · May 17, 2024
- ABVC reported Q1 revenue of $1,205 and a net loss of $3,981,019 (EPS $(0.40)), driven by sharply lower revenue versus prior year and large non-cash stock-based compensation. The company ended the quarter with $30,489 in…
- 10-Q · August 14, 2023
- ABVC reported a sharp revenue collapse to $6,109 for the quarter ended June 30, 2023 (Q2) versus $312,860 in Q2 2022 and posted net loss of $2,315,225 (net loss per share $(0.68)), worsening vs prior-year quarter.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ABVC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever